Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R T Silver

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
Leukemia|May 24, 2003
Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia veraR T Silver
Hematology/Oncology Clinics of North America|April 1, 1990
Chronic myeloid leukemia. A perspective of the clinical and biologic issues of the chronic phaseR T Silver
The American Journal of Medicine|April 1, 1980
The dying patient: a clinician's viewR T Silver
Blood|August 15, 1990
A new treatment for polycythemia vera: recombinant interferon alfaR T Silver
Current Opinion in Oncology|February 1, 1992
Chronic myeloid leukemiaR T Silver
Seminars in Hematology|July 1, 1990
Interferon in the treatment of myeloproliferative diseasesR T Silver
The New England Journal of Medicine|October 12, 1995
Hydroxyurea and sickle cell crisisR T Silver
Leukemia|October 29, 2004
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemiaR T Silver
Lancet (London, England)|August 13, 1988
Recombinant interferon-alpha for treatment of polycythaemia veraR T Silver
Seminars in Hematology|January 1, 1997
Interferon alfa: effects of long-term treatment for polycythemia veraR T Silver
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
Leukemia|May 24, 2003
Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia veraR T Silver
Hematology/Oncology Clinics of North America|April 1, 1990
Chronic myeloid leukemia. A perspective of the clinical and biologic issues of the chronic phaseR T Silver
The American Journal of Medicine|April 1, 1980
The dying patient: a clinician's viewR T Silver
Blood|August 15, 1990
A new treatment for polycythemia vera: recombinant interferon alfaR T Silver
Current Opinion in Oncology|February 1, 1992
Chronic myeloid leukemiaR T Silver
Seminars in Hematology|July 1, 1990
Interferon in the treatment of myeloproliferative diseasesR T Silver
The New England Journal of Medicine|October 12, 1995
Hydroxyurea and sickle cell crisisR T Silver
Leukemia|October 29, 2004
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemiaR T Silver
Lancet (London, England)|August 13, 1988
Recombinant interferon-alpha for treatment of polycythaemia veraR T Silver
Seminars in Hematology|January 1, 1997
Interferon alfa: effects of long-term treatment for polycythemia veraR T Silver
Pageof 14